2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
AuthorGalgiani, John N.
Ampel, Neil M.
Blair, Janis E.
Hoover, Susan E.
Johnson, Royce H.
MacDonald, Joel D.
Meyerson, Shari L.
Raksin, Patricia B.
Stevens, David A.
AffiliationUniv Arizona, Valley Fever Ctr Excellence
Univ Arizona, Div Infect Dis
Univ Arizona, Dept Rheumatol
community acquired pneumonia
MetadataShow full item record
PublisherOXFORD UNIV PRESS INC
Citation2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis 2016, 63 (6):e112 Clinical Infectious Diseases
JournalClinical Infectious Diseases
Rights© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractIt is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.
NoteFirst published online: July 27, 2016
VersionFinal published version
SponsorsInfectious Diseases Society of America (IDSA)